In January 2022, CLINUVEL announced that it had completed enrolment in its world-first study of afamelanotide as a treatment for arterial ischaemic stroke (AIS) patients. Following this news, CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, provides background on the importance of safety data at the early stages of an innovative clinical program. To read more about the CUV801 program, head to CLINUVEL’s website.